Catalyst Event
Biogen Inc (BIIB) · Other
From KEDI Palantir Fixed Tech100 Index (KPLTT100)
6/1/2026, 12:00:00 AM
Announced with partner UCB on 2026-06-01 that full results from the Phase 3 PHOENYCS GO trial of dapirolizumab pegol were published in The Lancet. A Low importance is estimated as journal publications usually have a limited impact on stock price, estimated.
Korean Translation
2026년 6월 1일, 협력사 UCB와 함께 전신성 홍반성 루푸스 치료제 다피롤리주맙 페골의 3상 임상 결과가 '더 랜싯'에 게재되었음을 발표함. 학술지 게재의 제한적인 시장 영향을 고려하여 중요도를 'Low'로 예상함.
Related Recent Events
Rocket Lab Corp (RKLB) · Earnings Release
Second Quarter 2026 financial results and conference call are scheduled for 2026-08-06 scheduled.
8/6/2026, 12:00:00 AM
Fortinet Inc (FTNT) · Earnings Release
Fortinet is scheduled to announce its Q2 2026 earnings results on August 5, 2026 expected. Medium importance estimated as earnings releases typically cause >5% price volatility.
8/5/2026, 12:00:00 AM
Teradyne Inc (TER) · Earnings Release
High importance is estimated as earnings reports typically drive significant volatility; Q2 2026 earnings release with revenue guidance of $1.15B-$1.25B and non-GAAP EPS of $1.86-$2.15 is scheduled.
8/4/2026, 12:00:00 AM
Axon Enterprise Inc (AXON) · Earnings Release
Market impact is estimated at Medium (>=5%) based on historical earnings volatility; Axon's Q2 2026 earnings report is scheduled.
8/3/2026, 12:00:00 AM
Sanofi (SNY) · Earnings Release
Sanofi is scheduled to release its Q2 2026 earnings results on July 30, 2026, expected.
7/30/2026, 12:00:00 AM
Amazon.com Inc (AMZN) · Earnings Release
Amazon's Q2 2026 earnings release is expected on July 30, 2026. The company guided for net sales between $194.0 billion and $199.0 billion. Low importance is assigned as the market reaction has not yet occurred expected.
7/30/2026, 12:00:00 AM